00:09:50 EDT Sun 31 May 2020
Enter Symbol
or Name

Login ID:
GeneNews Ltd (2)
Symbol GEN
Shares Issued 158,261,234
Close 2019-03-28 C$ 0.175
Recent Sedar Documents

GeneNews begins work on patient-directed testing

2019-03-28 10:12 ET - News Release

Mr. James Howard-Tripp reports


GeneNews Ltd. has launched the first of several initiatives to make patient-directed testing available nationwide.

GeneNews has partnered with PWNHealth, a national virtual care company that enables access to physicians who will facilitate and authorize diagnostic testing and provide guidance with test results. Patients will be able to purchase and initiate testing through an on-line portal at the My Cancer Risk website, where they can pay one flat fee for the test, the physician order and consult, and phlebotomy (blood draw) services.

Once an order is submitted, GeneNews will connect the patient with a physician in PWN's network who can prescribe the test and discuss the results with patients. Patients are advised to share their test reports with their regular health care providers so their results can be integrated into their existing medical records as well as current or future treatment plans.

In addition to providing access to a national provider network, GeneNews has built a national blood draw network that includes a combination of more than 8,000 draw sites and mobile phlebotomists through various partnerships with clinical laboratories.

"This initiative is something we've been working toward for two years," said James Howard-Tripp, chief executive officer of GeneNews. "We now have all the pieces in place -- the right tests, the physician network, nationwide blood draw capabilities and an IT infrastructure -- to launch a seamless patient directed testing model." Mr. Howard-Tripp added: "We get inquiries from patients every day on how they can access our tests, and we're excited to announce that we now have a process in place to meet their needs. We will continue to expand this capability over the coming months."

In 2018, the telehealth market was on track to grow to seven million patients with an anticipated growth rate of 18.5 per cent per year. Additional data report that 64 per cent of Americans were willing to use telehealth services.

It is anticipated that patient-directed testing will be fully operational by the end of April. The first test available for on-line purchase is the Prostate Health Index, a U.S. Food and Drug Administration-approved test that can help physicians differentiate prostate cancer from benign prostatic conditions in men with elevated PSA (prostate-specific antigen) levels. Patients can initiate a test order at the My Cancer Risk website.

About GeneNews Ltd.

GeneNews is dedicated to developing and commercializing innovative solutions for early cancer detection. The company's mission is to provide advanced diagnostics that can help physicians identify cancer in their patients at the earliest-possible stage (stage 0), when it is the most curable.

We seek Safe Harbor.

© 2020 Canjex Publishing Ltd. All rights reserved.